Abstract
Zoledronic acid is a parenteral aminobisphosphonate which is administered annually in the treatment of osteoporosis. It is an alternative to oral bisphosphonates, particularly in elderly patients with multiple comorbidities, because of its efficacy and intravenous route of administration. The most common side effects include post-dose reaction, renal dysfunction, and mild to moderate hypocalcemia. In this article, we report a 67-year-old male case of stroke during osteoporosis treatment of zoledronic acid within a day. Stroke development may be a coincidence, as the patient had stroke history and other risk factors for recurrent stroke. This case report highlights the possibility of zoledronic acid infusion-induced stroke with unusual side effects in geriatric patients.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
